Tetanus vaccination and risk of multiple sclerosis: A systematic review

Neurology

Volumn 67, Issue 2, 2006, Pages 212-215

  Hernán, Miguel A ^a   Alonso, Alvaro ^a   Hernández Díaz, Sonia ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TETANUS TOXOID;

ANAMNESIS; AUTHOR; CASE CONTROL STUDY; CELL HETEROGENEITY; COHORT ANALYSIS; CONFIDENCE INTERVAL; DATA ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; EMBASE; HUMAN; INCIDENCE; INFORMATION PROCESSING; INFORMATION RETRIEVAL; MEDLINE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PHYSICIAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCISEARCH; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; TETANUS PROPHYLAXIS; VACCINATION REACTION; VALIDATION PROCESS; VARIANCE; CLINICAL TRIAL; METHODOLOGY; PROGNOSIS; STATISTICS; VACCINATION;

CLINICAL TRIALS; HUMANS; INCIDENCE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; TETANUS TOXOID; VACCINATION;

EID: 33747073189     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000225079.51201.f9     Document Type: Review

References (21)

1. Verstraeten T, Davis R, DeStefano F. Immunity to tetanus is protective against the development of multiple sclerosis. Med Hypoth 2005;65:965-969.
2. DeStefano F, Verstraeten T, Jackson LA, et al. Vaccinations and risk of central nervous system demyelinating diseases in adults. Arch Neurol 2003;60:504-509.
3. Hernán MA, Jick SS, Olek MJ, Jick H. Recombinant hepatitis B vaccine and the risk of multiple sclerosis. A prospective study. Neurology 2004;63:838-842.
4. Etlinger HM, Gillessen D, Lahm HW, Matile H, Schonfeld HJ, Trzeciak A. Use of prior vaccinations for the development of new vaccines. Science 1990;249:423-425.
5. Vandenbark AA, Chou YK, Whitham R, et al. Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial. Nat Med 1996;2:1109-1115.
6. Takkouche B, Cadarso-Suárez C, Spiegelman D. Evaluation of old and new tests of heterogeneity in epidemiologic meta-analysis. Am J Epidemiol 1999;150:206-215.
7. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560.
8. Alter M, Speer J. Clinical evaluation of possible etiologic factors in multiple sclerosis. Neurology 1968;18:109-116.
9. Compston DAS, Vakarelis BN, Paul E, McDonald WI, Batchelor JR, Mims CA. Viral infection in patients with multiple sclerosis and HLA-DR matched controls. Brain 1986;109:325-344.
10. Zilber N, Kahana E. Risk factors for multiple sclerosis: a case-control study in Israel. Acta Neurol Scand 1996;94:395-403.
11. Kurtzke JF, Hyllested K, Arbuckle JD, et al. Multiple sclerosis in the Faroe Islands. 7. Results of a case control questionnaire with multiple controls. Acta Neurol Scand 1997;96:149-157.
12. Bansil S, Singhal BS, Ahuja GK, et al. Multiple sclerosis in India: a case-control study of environmental exposures. Acta Neurol Scand 1997;95:90-95.
13. Pekmezovic T, Jarebinski M, Drulovic J. Childhood infections as risk factors for multiple sclerosis: Belgrade Case-control Study. Neuroepidemiology 2004;23:285-288.
14. Casetta I, Granieri E, Malagu S, et al. Environmental risk factors and multiple sclerosis: a community-based, case-control study in the province of Ferrara, Italy. Neuroepidemiology 1994;13:120-128.
15. Lauer K, Firnhaber W. Das mögliche Risiko von Impfungen für die Erstmanifestation der multiplen Sklerose. Aktuelle Neurol 1990;17:42-46.
16. Verstraeten T, Davis R, DeStefano F, the Vaccine Safety Datalink Team. Decreased risk of demyelinating disease following tetanus immunization [abstract]. Am J Epidemiol 2002;155:S52.
17. Confavreux C, Suissa S, Saddier P, Bourdes V, Vukusic S. Vaccinations and the risk of relapse in multiple sclerosis. N Engl J Med 2001;344:319-326.
18. Chengalvala MV, Bhat RA, Bhat BM, Vernon SK, Lubeck MD. Enhanced immunogenicity of hepatitis B surface antigen by insertion of a helper T cell epitope from tetanus toxoid. Vaccine 1999;17:1035-1041.
19. Merkler D, Oertle T, Buss A, et al. Rapid induction of autoantibodies against Nogo-A and MOG in the absence of an encephalitogenic T cell response: implication for immunotherapeutic approaches in neurological diseases. FASEB J 2003;17:2275-2277.
20. Bourdette DN, Edmonds E, Smith C, et al. A highly immunogenic trivalent T cell receptor peptide vaccine for multiple sclerosis. Mult Scler 2005;11:552-561.
21. Vandenbark AA, Morgan E, Bartholomew R, et al. TCR peptide therapy in human autoimmune diseases. Neurochem Res 2001;26:713-730.